Syngene International Limited confirms financial guidance for fiscal 2023. Based on the nine-month results and the overall trajectory of the business, management reconfirms the guidance for the full year of high-teens revenue growth and an EBITDA margin of around 30%. PAT growth for the full year continues to be expected in the single digits.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
752 INR | +1.00% |
|
+3.85% | +7.21% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.21% | 3.61B | |
+23.59% | 47.96B | |
+0.11% | 42.45B | |
+43.96% | 41.47B | |
+25.91% | 31.6B | |
+19.44% | 28.63B | |
-4.47% | 28.03B | |
+51.34% | 14.56B | |
+43.72% | 14.14B | |
+2.03% | 12.58B |
- Stock Market
- Equities
- SYNGENE Stock
- News Syngene International Limited
- Syngene International Limited Confirms Financial Guidance for Fiscal 2023